The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Wolfgang Wick
Consultant or Advisory Role - Lilly; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; MSD
Timothy Francis Cloughesy
Consultant or Advisory Role - Apogenics; Celgene; Genentech; Merck; Merck Serono; NewGen Therapeutics; Roche; Tocagen
Ryo Nishikawa
Consultant or Advisory Role - Roche
Warren Mason
Consultant or Advisory Role - Roche
Frank Saran
Consultant or Advisory Role - Roche
Roger Henriksson
Consultant or Advisory Role - Roche
Honoraria - Roche
Magalie Hilton
Employment or Leadership Position - Roche
Yannick Kerloeguen
Employment or Leadership Position - Roche
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche